Thyroid transcription factor–1 (TTF-1) expression, routinely assessed through immunohistochemistry in the diagnostic evaluation of lung adenocarcinomas (LUADs), is negative (TTF-1Neg) in approximately 15% to 20% of cases. Although worse outcomes have been reported for these tumors compared with TTF-1–positive (TTF-1Pos) LUAD, a comprehensive characterization of TTF-1 negativity is currently lacking.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 12 Feb 2026.
The item focuses on TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.
Review the original article for the full source wording and details.